No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SAVA240705P10500
- 0.30
- +0.05+20.00%
15min DelayClose Jul 5 16:00 ET
0.70High0.09Low
0.25Open0.25Pre Close112 Volume0 Open Interest10.50Strike Price2.20KTurnover133.21%IV0.15%PremiumJul 5, 2024Expiry Date0.29Intrinsic Value100Multiplier0DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type-0.8019Delta0.8570Gamma31.92Leverage Ratio-0.2174Theta0.0000Rho-25.60Eff Leverage0.0007Vega
Intraday
- 5D
- Daily
News
Express News | FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; Once-Monthly Infusions Reduced Amyloid Plaques By...
Cassava Forms Committee After US Probe, Researcher Fraud
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Why Cassava Sciences Stock Is Sinking Today
Cassava Sciences Down Another 3% as SEC Provides Update on Simufilam Probe
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Cassava Sciences (NASDAQ:SAVA) has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employ
Comments
$Cassava Sciences(SAVA.US$ These are Caregivers speaking out. Thank to Matt N. SAVA's simufilam is working . All of those Fud, Hedge Funds & shorts are clearly manipulating the reputation and stock price of this company because it is actually treating AD patients and shorts have been trying to stop this. Do Not let them destroy the only safe drug with efficacy for AD patients. Phase 3 trials are almost done and plenty of people are improving.
2
$Cassava Sciences(SAVA.US$Why would people choose to stay on simufilan on extended trial if the drug didn’t work on a debilitating disease such as AD? AD gets violently worse over time . There’s never been an issue of safety and patient families and doctors testimony that sava works. 1900 people on this are not going to want to get off the drug and get worse again. The drug works
6
$Cassava Sciences(SAVA.US$ If we are going by ethics and integrity, did the DOJ ever investigate this’ Eisai and Biogen’s Alzheimer’s disease drug lecanemab’? Where was the outrage, DOJ investigation and accusations by Bik, Bredt, Adrian , Jesse and Shorts over death of patients in a drug that should have never been approved? 2 years ago when CUNY, SEC and FDA investigated, they found no evidence of wrongdoing or manipulation by SAVA or Wang. DOJ on a Friday afternoon before options expires wit...
4
Read more